Chronic hepatitis B (CHB) affects 350 million individuals worldwide. Perinatal transmission leads to high rates of chronic infection and complications, including cirrhosis and hepatocellular carcinoma. It is important to recognize and appropriately treat CHB in pregnancy, thereby reducing the risk of neonatal transmission and HBV-associated morbidity and mortality. Screening for CHB is recommended in all pregnant mothers as is universal vaccination of infants with hepatitis B virus (HBV) vaccine with or without hepatitis B immunoglobulin (HBIG). This has resulted in a lower incidence of HBsAg seropositivity and HCC in regions where universal infant vaccination has been endorsed. Mode of delivery and breastfeeding do not appear to affect HBV transmission rates based on available data. Overall, CHB does not increase perinatal maternal-fetal mortality. Administration of oral antiviral therapy during the third trimester to HBsAg-positive mothers with HBV DNA≥7 log IU/mL may be useful in preventing breakthrough infection. Treatment may be considered earlier in pregnancy for persistently active liver disease shown by high ALT, HBV DNA levels and/or significant hepatic fibrosis. Lamivudine, tenofovir and telbivudine are safe and effective and are the agents of choice in pregnancy. However, further clinical studies are necessary to elucidate the role of antiviral therapy in the pregnant HBV carrier. (Korean J Hepatol 2011;17:1-8)
INTRODUCTION
Chronic hepatitis B (CHB) in pregnancy is a prevalent and important problem with unique challenges. Over 50% of the world's 350 million carriers of CHB acquire the infection perinatally; in hepatitis B e antigen (HBeAg)-positive mothers, rates of transmission are as high as 90%. 1 The majority (> 95%) of perinatally acquired infection results in CHB infection, due to induction of an immune tolerant state of variable duration.
Worldwide, CHB remains a major health threat; each year approximately 600,000 individuals die of complications such as acute liver failure, cirrhosis, and hepatocellular carcinoma (HCC). 2 Therefore, prevention of perinatal transmission remains an important target in the struggle for global eradication of hepatitis B virus (HBV) infection.
The prevalence of hepatitis B surface antigen (HBsAg)-positive pregnant individuals varies with geographic location and ethnicity. In the USA, HBsAg prevalence is 6% in Asian women, 1% in African-Americans, 0.6% in non-Hispanic whites and 0.1% in Hispanics. 1 In endemic areas such as China and South East Asia, the prevalence may be as high as 10-20%. 3 Due to recent immigration patterns in North America, country of birth as well as ethnicity are important risk factors for perinatal acquisition of HBV.
This review will focus on strategies aimed at decreasing maternal-fetal transmission of CHB. HBsAg screening, HBV vaccination, mode of delivery and breastfeeding, and oral antiviral prophylaxis will be discussed. Based on studies of antiviral agents in pregnancy, we propose an algorithm for the prevention of perinatal transmission of HBV. In infants born to HBsAg-negative mothers, first HBV vaccine should be given before hospital discharge in full-term infants, and one month after birth or at hospital discharge in pre-term infants
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A large randomized placebo-controlled double-blind study of 155 HBeAg-positive women with HBV DNA≥1,000
Meq/ml but mainly normal ALT compared lamivudine 100 mg daily to placebo (Table 3) . 141 infants received immunoprophylaxis, but only 115 who received both HBV vaccine and HBIG were included in the final analysis. Mothers randomized to lamivudine received treatment beginning at 32 weeks gestational age and ending at 4 weeks post partum.
At 52 weeks post partum, 10/56 (18%) infants born to lamivudinetreated mothers remained HBsAg-positive compared to In this study, baseline HBV DNA was > 6 log copies/mL and ALT >40 IU/mL but less than 10× upper limit of normal. All infants received active and passive immunization. At birth, 4% and 23% the newborns were HBsAg-positive in the telbivudine and control groups, respectively (P<0.001).
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Although these data are promising, more studies with longer follow-up are needed.
Safety data on antiviral therapy are primarily derived from clinical studies and the antiretroviral pregnancy registry, a prospective registry mainly for HIV-positive individuals.
As of 2010, only 112 women with HBV mono-infection were therapy are estimated to be 2.7% live births, which is comparable to prevalence in the general population. 18 The FDA has classified entecavir, lamivudine, and adefovir as category C medications, whereas telbivudine and tenofovir are category B medications. Interferon has been classified as category X (Table 4 ).
The advantages of antiviral therapy during pregnancy include: potent antiviral suppression, relative safety and tolerability in pregnancy and, ultimately, a reduction in perinatal HBV transmission. Disadvantages include the risk of developing antiviral resistance in the mother depending on the antiviral agent used, contraindication to breastfeeding, and the risk of hepatitis flares upon discontinuation of therapy.
In one study involving 31 HBeAg-positive and negative mothers, a postpartum flare defined as threefold increase in alanine amino transferase (ALT) occurred in 62% of lamivudine-treated mothers who discontinued therapy, compared with 42% of untreated mothers. 19 Given limited long-term safety and efficacy data on antiviral therapy in pregnancy, the decision to initiate treatment should be made on a case-by-case basis.
In clinical practice, HBV DNA levels are measured during the second trimester in all pregnant HBsAg-positive mothers (Fig. 1) . If HBV DNA is ≥7 log IU/mL then prophylactic treatment beginning in the early third trimester with lamivudine, tenofovir or telbivudine should be considered.
Counseling should be provided regarding goals of treatment, treatment duration, potential side effects, overall safety in pregnancy for mother and fetus, monitoring on treatment and breastfeeding. If the mother decides to breast feed her infant, then all antiviral therapy must be discontinued at birth, in order to limit exposure to the infant. In addition, standard vaccination schedules are to be followed. 
